Literature DB >> 17210196

Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1.

Masafumi Shimojo1, Naruhiko Sahara, Miyuki Murayama, Hiroshi Ichinose, Akihiko Takashima.   

Abstract

Presenilin (PS) is a catalytic subunit of the gamma-secretase complex that cleaves the intramembranous region of amyloid precursor protein (APP), producing amyloid beta (Abeta) peptide. Familial Alzheimer's disease (FAD) results from PS mutations, which may alter gamma-secretase activity to enhance the production of highly aggregable Abeta42. The precise pathogenic effects of mutant PS remain unclear. To exclude the effects of endogenous PS, we established cell lines from PS1/PS2-deficient (PS-/-) fibroblasts capable of stably expressing either wild-type (wt) PS1 or different mutant PS1s. Although both wt PS1 and mutant PS1 formed gamma-secretase complexes of the same size and containing the same components, the amount of Abeta secreted by FAD mutant PS1-expressing cells was significantly reduced. The ratio of Abeta42 to Abeta40 (Abeta42/Abeta40) secreted by these cells, however, was significantly higher than that secreted by cells expressing wt PS1, which corroborated findings from a previous report. The elevated Abeta42/Abeta40 ratio observed with mutant PS1-expressing cells may be due to reduced Abeta40 production not increased Abeta42 production.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210196     DOI: 10.1016/j.neures.2006.12.005

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  12 in total

1.  Amyloid precursor protein and tau transgenic models of Alzheimer's disease: insights from the past and directions for the future.

Authors:  Naruhiko Sahara; Jada Lewis
Journal:  Future Neurol       Date:  2010-05-01

2.  Dissociation between the processivity and total activity of γ-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations.

Authors:  Omar Quintero-Monzon; Morgan M Martin; Marty A Fernandez; Christina A Cappello; Amanda J Krzysiak; Pamela Osenkowski; Michael S Wolfe
Journal:  Biochemistry       Date:  2011-09-30       Impact factor: 3.162

3.  A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity.

Authors:  Elizabeth A Heilig; Weiming Xia; Jie Shen; Raymond J Kelleher
Journal:  J Biol Chem       Date:  2010-05-11       Impact factor: 5.157

4.  Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase.

Authors:  Linfeng Sun; Rui Zhou; Guanghui Yang; Yigong Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-05       Impact factor: 11.205

Review 5.  Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease.

Authors:  Lina Adwan; Nasser H Zawia
Journal:  Pharmacol Ther       Date:  2013-04-03       Impact factor: 12.310

6.  Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease.

Authors:  E Hellström-Lindahl; M Viitanen; A Marutle
Journal:  Neurochem Int       Date:  2009-03-20       Impact factor: 3.921

7.  Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease.

Authors:  Sascha Weggen; Dirk Beher
Journal:  Alzheimers Res Ther       Date:  2012-03-30       Impact factor: 6.982

8.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease.

Authors:  Lucía Chávez-Gutiérrez; Leen Bammens; Iryna Benilova; Annelies Vandersteen; Manasi Benurwar; Marianne Borgers; Sam Lismont; Lujia Zhou; Simon Van Cleynenbreugel; Hermann Esselmann; Jens Wiltfang; Lutgarde Serneels; Eric Karran; Harrie Gijsen; Joost Schymkowitz; Frederic Rousseau; Kerensa Broersen; Bart De Strooper
Journal:  EMBO J       Date:  2012-04-13       Impact factor: 11.598

9.  Bax inhibitor 1 is a γ-secretase-independent presenilin-binding protein.

Authors:  Shenjie Wu; Wenqi Song; Catherine C L Wong; Yigong Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

Review 10.  Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β.

Authors:  Jeremy H Toyn; Michael K Ahlijanian
Journal:  Alzheimers Res Ther       Date:  2014-03-12       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.